EP1402051A4 - Lces as modifiers of the p53 pathway and methods of use - Google Patents

Lces as modifiers of the p53 pathway and methods of use

Info

Publication number
EP1402051A4
EP1402051A4 EP02732039A EP02732039A EP1402051A4 EP 1402051 A4 EP1402051 A4 EP 1402051A4 EP 02732039 A EP02732039 A EP 02732039A EP 02732039 A EP02732039 A EP 02732039A EP 1402051 A4 EP1402051 A4 EP 1402051A4
Authority
EP
European Patent Office
Prior art keywords
lces
modifiers
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02732039A
Other languages
German (de)
French (fr)
Other versions
EP1402051A2 (en
Inventor
Lori Friedman
Gregory D Plowman
Marcia Belvin
Helen Francis-Lang
Danxi Li
Roel P Funke
Felix D Karim
Linda N Keyes
Thomas I Koblizek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of EP1402051A2 publication Critical patent/EP1402051A2/en
Publication of EP1402051A4 publication Critical patent/EP1402051A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
EP02732039A 2001-06-05 2002-06-03 Lces as modifiers of the p53 pathway and methods of use Withdrawn EP1402051A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US29607601P 2001-06-05 2001-06-05
US296076P 2001-06-05
US32860501P 2001-10-10 2001-10-10
US328605P 2001-10-10
US35725302P 2002-02-15 2002-02-15
US357253P 2002-02-15
US36119602P 2002-03-01 2002-03-01
US361196P 2002-03-01
PCT/US2002/017739 WO2002099068A2 (en) 2001-06-05 2002-06-03 Lces as modifiers of the p53 pathway and methods of use

Publications (2)

Publication Number Publication Date
EP1402051A2 EP1402051A2 (en) 2004-03-31
EP1402051A4 true EP1402051A4 (en) 2005-08-17

Family

ID=27501675

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02732039A Withdrawn EP1402051A4 (en) 2001-06-05 2002-06-03 Lces as modifiers of the p53 pathway and methods of use
EP02741809A Withdrawn EP1402262A4 (en) 2001-06-05 2002-06-03 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02741809A Withdrawn EP1402262A4 (en) 2001-06-05 2002-06-03 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE

Country Status (5)

Country Link
EP (2) EP1402051A4 (en)
JP (2) JP2004532638A (en)
AU (1) AU2002314887A1 (en)
CA (2) CA2448112A1 (en)
WO (4) WO2002098889A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (en) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
AU2012233044B2 (en) * 2002-11-22 2015-09-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
EP1572118A4 (en) * 2002-12-20 2010-07-14 Millennium Pharm Inc Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
DE10316701A1 (en) * 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. New nucleic acid, and derived proteins, useful for diagnosis of bronchial cancer and in screening for therapeutic and diagnostic agents
EP1657311A4 (en) * 2003-07-11 2006-10-11 Banyu Pharma Co Ltd Method of evaluating compound efficacious in treating obesity
EP1677739A4 (en) * 2003-09-04 2008-07-23 Immusol Inc Methods of identifying agents that inhibit the growth of cancer cells
WO2005083425A2 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 13 (map3k13)
US7622367B1 (en) 2004-06-04 2009-11-24 The Board Of Trustees Of The University Of Illinois Methods and devices for fabricating and assembling printable semiconductor elements
JP5700750B2 (en) 2007-01-17 2015-04-15 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ Optical system manufactured by printing base assembly
KR101706915B1 (en) 2009-05-12 2017-02-15 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 Printed assemblies of ultrathin, microscale inorganic light emitting diodes for deformable and semitransparent displays
US9442285B2 (en) 2011-01-14 2016-09-13 The Board Of Trustees Of The University Of Illinois Optical component array having adjustable curvature
US9765934B2 (en) 2011-05-16 2017-09-19 The Board Of Trustees Of The University Of Illinois Thermally managed LED arrays assembled by printing
EP2713863B1 (en) 2011-06-03 2020-01-15 The Board of Trustees of the University of Illionis Conformable actively multiplexed high-density surface electrode array for brain interfacing
CN104472023B (en) 2011-12-01 2018-03-27 伊利诺伊大学评议会 It is designed to undergo the transient state device of programmable transformation
CN114181944B (en) * 2020-09-14 2023-10-03 中国科学院动物研究所 Mutant gene, method for constructing miniature pig model of short-limb dwarfism and application

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000065054A2 (en) * 1999-04-23 2000-11-02 Incyte Genomics, Inc. Human membrane-associated proteins
WO2001034643A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001098353A2 (en) * 2000-06-20 2001-12-27 Incyte Genomics, Inc. Secreted proteins
WO2002044320A2 (en) * 2000-11-29 2002-06-06 Xenon Genetics Inc. Human elongase genes and uses thereof
WO2002062974A2 (en) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation of human elongase hselo1-like protein
WO2002063006A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Receptors and membrane-associated proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014485A1 (en) * 1991-02-22 1992-09-03 Amrad Corporation Limited A method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5554523A (en) * 1994-03-01 1996-09-10 Children's Hospital Of Philadelphia Nucleic acid sequences encoding human leucine-zipper protein-kinase
AU3289599A (en) * 1998-02-13 1999-08-30 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
WO1999047686A2 (en) * 1998-03-16 1999-09-23 Cadus Pharmaceutical Corporation Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
EP1161542A1 (en) * 1999-03-18 2001-12-12 University Of Bristol Polysaturated fatty acid (pufa) elongase from caenorhabditis elegans
CA2342831A1 (en) * 1999-07-22 2001-02-01 The University Of British Columbia A plant long chain fatty acid biosynthetic enzyme
CA2418266A1 (en) * 2000-08-11 2002-02-21 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel mitogen activated kinase
WO2002062975A2 (en) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation of human elongase hselo1-like protein
WO2002096943A1 (en) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
WO2003091419A2 (en) * 2002-04-24 2003-11-06 Incyte Corporation Kinases and phosphatases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000065054A2 (en) * 1999-04-23 2000-11-02 Incyte Genomics, Inc. Human membrane-associated proteins
WO2001034643A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001098353A2 (en) * 2000-06-20 2001-12-27 Incyte Genomics, Inc. Secreted proteins
WO2002044320A2 (en) * 2000-11-29 2002-06-06 Xenon Genetics Inc. Human elongase genes and uses thereof
WO2002063006A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Receptors and membrane-associated proteins
WO2002062974A2 (en) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation of human elongase hselo1-like protein

Also Published As

Publication number Publication date
EP1402262A4 (en) 2005-05-11
WO2002099068A3 (en) 2003-12-04
CA2449479A1 (en) 2002-12-12
WO2002098889A2 (en) 2002-12-12
CA2448112A1 (en) 2002-12-12
WO2002098468A1 (en) 2002-12-12
EP1402262A2 (en) 2004-03-31
WO2002098891A2 (en) 2002-12-12
AU2002314887A1 (en) 2002-12-16
WO2002099068A2 (en) 2002-12-12
JP2004532638A (en) 2004-10-28
JP2005514906A (en) 2005-05-26
EP1402051A2 (en) 2004-03-31
WO2002098891A3 (en) 2003-05-30
WO2002098889A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
EP1401475A4 (en) Prmts as modifiers of the p53 pathway and methods of use
EP1421384A4 (en) Hprp4s as modifiers of the p53 pathway and methods of use
AU2003224638A8 (en) Pdpk1s as modifiers of the p53 pathway and methods of use
AU2002364528A8 (en) Bio-implant and method of making the same
AU2002352903A8 (en) Mesoporous materials and methods
EP1402051A4 (en) Lces as modifiers of the p53 pathway and methods of use
EP1434772A4 (en) Compounds and methods
AU2002239933A1 (en) Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
AU2002337916A1 (en) Modifier of the p53 pathway and methods of use
AU2002359694A8 (en) Compounds and methods
EP1418194A4 (en) Modified polyalkyleneimine and methods of using the same
EP1379240A4 (en) Compounds and methods
AU2003295881A8 (en) Lamps as modifiers of the p53 pathway and methods of use
AU2003303094A8 (en) Mat2as as modifiers of the p53 pathway and methods of use
AU2002357817A8 (en) Klcs as modifiers of the p53 pathway and methods of use
AU2001268903A1 (en) Hexaglucal compound and the use and the methods of preparing them
AU2002345486A1 (en) Slc13as as modifiers of the p53 pathway and methods of use
AU2002303947A1 (en) Pecis as modifiers of the p53 pathway and methods of use
AU2002312283A1 (en) Srpks as modifiers of the p53 pathway and methods of use
AU2002303951A1 (en) Glras as modifiers of the p53 pathway and methods of use
AU2002314874A1 (en) Modifiers of the p53 pathway and methods of use
AU2002361654A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2002332130A1 (en) Msrebps as modifiers of the srebp pathway and methods of use
EP1435953A4 (en) Antivesicant compounds and methods of making and using thereof
AU2003278811A8 (en) Ldlrs as modifiers of the p53 pathway and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050624

17Q First examination report despatched

Effective date: 20050923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070326